Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DR39GZ
|
|||
| Drug Name |
BNT116
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Phase 2 | [1] | |
| Company |
BioNTech
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05557591) A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 >=50%. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.